Antimicrobials for Candida infections - EUCAST clinical MIC breakpoints                2011-04-27 (v 3.0)

Antifungal

Click on antimicrobial name to see wild type MIC distributions

  Species-related breakpoints (S</R>)  Non-species related breakpointsA
S</R>
Candida
albicans
Candida
glabrata
Candida
krusei
Candida
parapsilosis
Candida
tropicalis
Candida guilliermondii      
Amphotericin B RD 1/1 1/1 1/1 1/1 1/1 IE       IE
Anidulafungin RD 0.03/0.03 0.06/0.06 0.06/0.06 -- 0.06/0.06 IE       IE
Fluconazole RD 2/4 IE -- 2/4 2/4         2/4
Posaconazole RD 0.06/0.06 IE IE 0.06/0.06 0.06/0.06 IE       IE
Voriconazole RD 0.125/0.125B IE IE 0.125/0.125B 0.125/0.125B         IE
                       

 

 

A. Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.

B. Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint (in italics) they should be reported resistant.

 -- = Susceptibility testing not recommended as the species is a poor target for therapy with the drug.
"IE" indicates that there is insufficient evidence that the species in question is a good target for therapy with the drug. A MIC with a comment but without an accompanying S, I or R-categorization may be reported.
 RD =Rationale document listing data used for setting EUCAST breakpoints.

 

Version*  Date Action
3.0 2011-04-27 Clinical breakpoints for amphotericin B, posaconazole and anidulafungin were added to tables.
2.2 2010-03-22 Voriconazole Candida krusei breakpoint changed from "--" to "IE" and Rationale Document by the EUCAST Subcommittee on Antifungal Susceptibility Testing (EUCAST AFST) updated.
2.1 2008-08-27 Voriconazole Rationale Document by the EUCAST Subcommittee on Antifungal Susceptiubility Testing (EUCAST AFST) published on EUCAST website
2.0 2008-07-24 Voriconazole breakpoints as  determined by the EUCAST Subcommittee on Antifungal Susceptibility Testing (EUCAST AFST) made publicly available
1.0 2007-07-10 Fluconazole breakpoints as determined by the EUCAST Subcommittee on Antifungal Susceptibility Testing (EUCAST AFST) made publicly available
*The number before the point indicates breakpoint change. The number after the point indicates minor changes (footnotes, spelling, format, etc) without a change of breakpoints.